论文部分内容阅读
本文最初发表于2016年《J Hematol Oncol》杂志上,文章题录为:Yan CH,Wang Y,Wang JZ,et al.Minimal residual disease and graft-versus-host disease guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukaemia relapse after allotransplant[J].J Hematol Oncol,2016,9:87。本研究证实,在异基因造血干细胞移植(allo-HSCT)后出现血液学复发的急性白血病、且经过诱导化疗+DLI达到完全缓解的患者中,MRD和GvHD指导下的多次巩固化疗+DLI可以预防再次复发,避免不必要的非复发死亡,最终改善生存。这项研究第一次强调了巩固化疗+DLI在治疗allo-HSCT后急性白血病复发中的作用。这将会成为治疗allo-HSCT后急性白血病复发的新方法。经通信作者许可,再次通过佳文解读的方式来阐述这一发现。
This article was originally published in the 2016 issue of J Hematol Oncol, titled: Yan CH, Wang Y, Wang JZ, et al. Mimal residual disease and graft-versus-host disease guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukaemia relapse after allotransplant [J]. J Hematol Oncol, 2016, 9: 87. This study demonstrates that MRD and GvHD-directed multiple myeloablative chemotherapy plus DLI in patients with hematologic relapsed acute leukemia following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and complete remission after induction of chemotherapy plus DLI can Prevent relapse again, avoid unnecessary non-recurrence of death, and ultimately improve survival. This study for the first time highlights the role of consolidation chemotherapy plus DLI in the treatment of relapsed acute leukemia after allo-HSCT. This will be a new way to treat the recurrence of acute leukemia after allo-HSCT. With the permission of the author of the communication, this finding is again elaborated through the interpretation of the article.